ACS Biomater Sci Eng

1. LI X, Xie J, Song SJ, Ahlquist CSE, et al
   Sialic Acid Binding Liposome Nanoparticles for Targeted Bladder Cancer Therapy.
   ACS Biomater Sci Eng. 2026 Jan 7. doi: 10.1021/acsbiomaterials.5c01546.
   

   >> Share

   
   

   
   Actas Urol Esp (Engl Ed)

2. SAOULI A, Contieri R, Quhal F, Hurle R, et al
   Efficacy and safety of active surveillance and chemoablation in the management of non-muscle invasive bladder cancer (NMIBC): Systematic review and pooled analysis by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma
   Actas Urol Esp (Engl Ed). 2026 Jan 5:501917. doi: 10.1016/j.acuroe.2026.501917.
   

   >> Share

   
   
3. DIANA P, Gallioli A, Uleri A, Mas L, et al
   Attendings versus supervised residents: Educational results and future perspective in transurethral resection of bladder tumors.
   Actas Urol Esp (Engl Ed). 2026;50:501830.
   

   >> Share

   
   

   
   Am J Mens Health

4. SHI G, Zhou X, Yang F, Wang T, et al
   Harnessing Ubiquitin-Proteasome System-Related Genes to Identify Subtypes of Bladder Cancer and Reveal Immune Landscape.
   Am J Mens Health. 2026;20:15579883251410519.
   

   >> Share

   
   

   
   Ann Med

5. ABOU CHAKRA M, Boormans JL, Hayne D, O'Donnell MA, et al
   Strategic sequencing of bladder-sparing therapies in the management of BCG-unresponsive non-muscle invasive bladder cancer.
   Ann Med. 2026;58:2612387.
   

   >> Share

   
   

   
   Arch Esp Urol

6. ILKTAC A, Ersoz C, Kalkan S, Dogan B, et al
   Bleeding Risks in Urologic Surgery: A Prospective Analysis of Anticoagulant and Antiaggregant Use in Transurethral Resection of Prostate, Transurethral Resection of Bladder Tumour and Open Prostatectomy.
   Arch Esp Urol. 2025;78:1392-1400.
   

   >> Share

   
   
7. FU Q, Yan F, Sun Z, Yao Z, et al
   Analysis of Urinary Continence, Complications, and Urodynamic Characteristics Following Orthotopic Ileocaecal Neobladder Reconstruction: A Preliminary Study on Safety and Feasibility.
   Arch Esp Urol. 2025;78:1493-1500.
   

   >> Share

   
   

   
   Arch Ital Urol Androl

8. BUZOIANU M, Buhas BA, Abou Chakra M, Ionutas E, et al
   A national perspective on the management of high-risk BCG-unresponsive non-muscle-invasive bladder cancer in Romania.
   Arch Ital Urol Androl. 2025;97:14596.
   

   >> Share

   
   
9. FALABELLA R, Porreca A, Foschi N, Salvaggio A, et al
   Robotic bladder diverticulectomy in patients with bladder diverticulum neoplasia: a single-center study.
   Arch Ital Urol Androl. 2025;97:14467.
   

   >> Share

   
   
10. PEREIRA JA, Vieira-Brito D, Ferreira AM, Marques R, et al
    Hyperthermic vs normothermic mitomycin C for intermediate-risk NMIBC: a real-world retrospective cohort study.
    Arch Ital Urol Androl. 2025;97:14167.
    

    >> Share

    
    

    
    Biomol Biomed

11. ZHANG T, Zhang X, Qian L, Hu C, et al
    Molecular and immune characteristics of neuroendocrine bladder carcinoma - Implications for diagnosis, prognosis, and therapy: A review.
    Biomol Biomed. 2025;26:711-719.
    

    >> Share

    
    

    
    bioRxiv

12. PIZZI JR, Adhikari I, Prakash P, Miyamoto H, et al
    Machine-learning-based determination of sex-related bladder cancer biomarkers.
    bioRxiv [Preprint]. 2025 Dec 23:2025.12.20.695175.
    

    >> Share

    
    

    
    BJU Int

13. PELLEGRINO F, de Angelis M, Scilipoti P, Longoni M, et al
    Temporal trends and clinical determinants of urinary diversion after radical cystectomy.
    BJU Int. 2026;137:323-331.
    

    >> Share

    
    
14. SUBIELA JD, de la Parra I, Taborda J, Medina AA, et al
    Defining statistical cure in patients with T1 high-grade non-muscle-invasive bladder carcinoma treated with BCG immunotherapy.
    BJU Int. 2026;137:270-281.
    

    >> Share

    
    

    
    BMC Urol

15. WANG H, Xiong Y, He T, He M, et al
    MXRA8, a key palmitoylation-related gene, promotes bladder cancer progression via remodeling tumor microenvironment and predicts poor prognosis.
    BMC Urol. 2026 Jan 8. doi: 10.1186/s12894-026-02046.
    

    >> Share

    
    

    
    BMJ Case Rep

16. ADMIRE K, Gegick S
    Transvascular endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA) to confirm urothelial carcinoma metastasis to the pulmonary artery.
    BMJ Case Rep. 2026;19:e268157.
    

    >> Share

    
    

    
    Cancer Cell Int

17. XU D, Jacob JJ, Wieczorek K, Wang L, et al
    Modeling primary immunotherapy resistance in metastatic bladder cancer: a syngeneic, bioluminescent mouse model.
    Cancer Cell Int. 2026 Jan 8. doi: 10.1186/s12935-025-04117.
    

    >> Share

    
    

    
    Cancer Diagn Progn

18. MINATO A, Jojima K, Watanabe S, Sugita Y, et al
    Recurrence of Low-risk Non-muscle-invasive Bladder Cancer in Patients Who Did Not Receive Immediate Intravesical Chemotherapy.
    Cancer Diagn Progn. 2026;6:135-143.
    

    >> Share

    
    

    
    Cancer Imaging

19. BAI R, Cai L, Jiang M, Wang C, et al
    Development and validation of MRI-based models to predict lymph node metastasis in bladder cancer: a multi-center study.
    Cancer Imaging. 2026 Jan 7. doi: 10.1186/s40644-025-00984.
    

    >> Share

    
    

    
    Cancer Immunol Res

20. YANG FH, Zhang W, Wang R, Mao S, et al
    Pseudomonas aeruginosa exacerbates bladder cancer progression by activating cancer-driven immunosuppression.
    Cancer Immunol Res. 2026 Jan 9. doi: 10.1158/2326-6066.CIR-25-0873.
    

    >> Share

    
    

    
    Cancer Med

21. WANG J, Lu Q, Jiao P, Jian J, et al
    Machine Learning Integration Framework Constructs a Lactylation-Associated Gene Signature to Improve Prognosis in Bladder Cancer.
    Cancer Med. 2026;15:e71477.
    

    >> Share

    
    

    
    Cancers (Basel)

22. JAROMIN M, Kutwin P, Konecki T, Popiela D, et al
    Inflammation Indices as Predictive Markers of Muscle-Invasive Bladder Cancer.
    Cancers (Basel). 2025;18:136.
    

    >> Share

    
    

    
    Chem Biol Interact

23. LIU P, Zhang L, Zhou Q, Fu Z, et al
    STIM1 N-linked glycosylation promotes arsenic-induced malignant phenotype by activating SOCE in bladder epithelial cells.
    Chem Biol Interact. 2026;424:111866.
    

    >> Share

    
    

    
    Chin Clin Oncol

24. YUAN J, Yu S, Zheng J
    Epidemiological trends and future projections of bladder and kidney cancer burden in China, 1990-2041: an ecological study.
    Chin Clin Oncol. 2025;14:71.
    

    >> Share

    
    

    
    Clin Exp Med

25. LI Y, Zhao B, Gao W, Wu Y, et al
    Correction: LDB2 is a novel diagnostic and prognostic biomarker and inhibits bladder cancer metastasis by activating p38 MAPK/ERK1/2/JNK signaling pathway.
    Clin Exp Med. 2026;26:62.
    

    >> Share

    
    

    
    Diagnostics (Basel)

26. JAIN M, Tivtikyan A, Kislyakov D, Rakhmatullin T, et al
    The Diagnostic Performance of a Four-Gene Digital Droplet PCR Panel for Urine Liquid Biopsy in Urothelial Bladder Cancer.
    Diagnostics (Basel). 2025;16:69.
    

    >> Share

    
    

    
    Eur Urol Oncol

27. MAY M, Wolff I, Brookman-May S, Burger M, et al
    Re: Paramananthan Mariappan, Jasmin Hart-Brooke, Rebecca Sparks, Tanya Lord-McKenzie. Bladder EpiCheck Triggered Photodynamic Diagnosis Biopsies Detect High-grade Bladder Cancer Recurrences Missed by White Light Cystoscopy. Eur Urol Oncol. In press. h
    Eur Urol Oncol. 2026 Jan 3:S2588-9311(25)00341-4. doi: 10.1016/j.euo.2025.
    

    >> Share

    
    

    
    Exp Cell Res

28. WANG Y, Liu H, Wang T, Yang Y, et al
    GLRX5 is a prognostic marker in bladder cancer and correlates with activation of cancer-associated fibroblasts in the tumor microenvironment.
    Exp Cell Res. 2026;455:114884.
    

    >> Share

    
    
29. HE K, Lin C, Wang H, Wu H, et al
    The circ-GLG1/miR-346/KCNJ9 axis drives malignant progression of bladder cancer by modulating KCNJ9 expression.
    Exp Cell Res. 2026;455:114885.
    

    >> Share

    
    

    
    Expert Rev Anticancer Ther

30. YU EM, Linville L, Hwang MW, Kim Y, et al
    Harnessing genomic profiling for improved urothelial cancer outcomes.
    Expert Rev Anticancer Ther. 2026;26:93-104.
    

    >> Share

    
    

    
    FASEB J

31. JIN Z, Yang W, Peng Y, Ma L, et al
    HOXB4 Promotes Bladder Cancer Progression in Part Through Transcriptional Activation of Smoothened.
    FASEB J. 2026;40:e71388.
    

    >> Share

    
    

    
    Hinyokika Kiyo

32. SAITO M, Kakoi N, Izumi M, Aoki H, et al
    [A Case of Verrucous Carcinoma of the Bladder in a Patient with Cerebral Palsy].
    Hinyokika Kiyo. 2025;71:425-428.
    

    >> Share

    
    

    
    Int J Mol Sci

33. NAKAGAWA Y, Yamamoto C, Kawajiri H, Watanabe M, et al
    Whole Genome Sequencing of Clinical Mycobacterium bovis BCG in Disseminated Infection with Mycotic Aneurysm and ARDS After Intravesical Therapy: A Case Report.
    Int J Mol Sci. 2025;27:238.
    

    >> Share

    
    
34. TRILLA-FUERTES L, Pedregosa-Barbas J, Garcia-Fernandez E, Zambrana F, et al
    Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers.
    Int J Mol Sci. 2026;27:476.
    

    >> Share

    
    

    
    Int J Surg Pathol

35. CHENG AV, Bardell J, Sangoi AR
    Collision of Presumed Primary Urinary Bladder Malignant Melanoma and Invasive Urothelial Carcinoma: A Case Report.
    Int J Surg Pathol. 2026;34:201-206.
    

    >> Share

    
    
36. KAYAR K, Dogan MB, Karabay E
    A Rare Presentation of Alveolar Soft Part Sarcoma in the Bladder.
    Int J Surg Pathol. 2026;34:158-161.
    

    >> Share

    
    

    
    Intern Med

37. HISANAGA E, Sano T, Yokoo H
    Four Metachronous Cancers: Mutation Profiling Can Be Used to Distinguish Multiple Primary Cancers from Metastases.
    Intern Med. 2026;65:183-186.
    

    >> Share

    
    

    
    J Biomed Sci

38. CHIANG Y, Tsai YC, Wang CC, Hsueh FJ, et al
    High-CD14-expressing urothelial cancer cells foster a neutrophil-rich tumor microenvironment that increases the risk of radiation-promoted distant metastasis.
    J Biomed Sci. 2026;33:2.
    

    >> Share

    
    

    
    J Cancer Res Clin Oncol

39. HESSE M, Iltzsche M, Nahhas D, Thomas C, et al
    Type I-interferon beta induces a strong anti-tumour response in bladder cancer cells.
    J Cancer Res Clin Oncol. 2026;152:35.
    

    >> Share

    
    
40. BASU M, Chatterjee A, Chakraborty B, Chatterjee E, et al
    Retraction Note: High nuclear expression of HIF1alpha, synergizing with inactivation of LIMD1 and VHL, portray worst prognosis among the bladder cancer patients: association with arsenic prevalence.
    J Cancer Res Clin Oncol. 2026;152:26.
    

    >> Share

    
    

    
    J Clin Med

41. HARSANYI S, Novakova ZV, Neuschlova L, Galbavy S, et al
    Optimizing Ki-67 and E-Cadherin Thresholds for Improved Grade and Stage Classification in Urothelial Bladder Cancer.
    J Clin Med. 2026;15:338.
    

    >> Share

    
    

    
    J Nanobiotechnology

42. WU Z, Zeng J, Feng L, Zhu X, et al
    Tumor-homing cerium nanozyme platform enables coordinated drug release and STING activation for bladder cancer treatment.
    J Nanobiotechnology. 2026 Jan 10. doi: 10.1186/s12951-025-03955.
    

    >> Share

    
    

    
    J Robot Surg

43. ORAKZAI FK, Mirza W, Khan ME, Iqbal H, et al
    Robot-assisted versus open radical cystectomy with extracorporeal urinary diversion for bladder cancer: a GRADE-assessed systematic review and meta-analysis of randomized controlled trials with subgroup analyses by orthotopic neobladder utilisation.
    J Robot Surg. 2026;20:151.
    

    >> Share

    
    

    
    JCO Oncol Pract

44. RAGHAVAN D
    Sad But True: Inconsistent Care for Invasive Bladder Cancer.
    JCO Oncol Pract. 2026 Jan 9:OP2501254. doi: 10.1200/OP-25-01254.
    

    >> Share

    
    

    
    Jpn J Clin Oncol

45. GATELLIER L, Nakata K
    Age-standardized mortality-to-incidence ratio for bladder cancer in the world.
    Jpn J Clin Oncol. 2026;56:115-116.
    

    >> Share

    
    

    
    Nat Commun

46. SINGH P, D'Rozario R, Chakraborty B, Meher S, et al
    Loss of KDM6A-mediated genomic instability and metabolic reprogramming regulates response to therapeutic perturbations in bladder cancer.
    Nat Commun. 2026 Jan 7. doi: 10.1038/s41467-025-68132.
    

    >> Share

    
    
47. STURDIVANT MS, Truong AS, Zhou M, Toomer ED, et al
    APOBEC3 promotes squamous differentiation via IL-1A/AP-1 signaling.
    Nat Commun. 2025;17:334.
    

    >> Share

    
    

    
    Nat Rev Clin Oncol

48. ST-LAURENT MP, Nikkola J, Tomiyama E, Black PC, et al
    Advances in the management of localized bladder cancers.
    Nat Rev Clin Oncol. 2026 Jan 5. doi: 10.1038/s41571-025-01104.
    

    >> Share

    
    

    
    Oxid Med Cell Longev

49. CELLULAR LONGEVITY OMA
    RETRACTION: lncRNA OTUD6B-AS1 Exacerbates As(2)O(3)-Induced Oxidative Damage in Bladder Cancer via miR-6734-5p-Mediated Functional Inhibition of IDH2.
    Oxid Med Cell Longev. 2025;2025:9894089.
    

    >> Share

    
    

    
    Proc Natl Acad Sci U S A

50. DARJI S, Qu F, Henager M, Prasad A, et al
    Optimizing mRNA delivery with targeted elastin-like polypeptide-based LENN formulations: Insights into the endocytosis mechanism.
    Proc Natl Acad Sci U S A. 2026;123:e2502486122.
    

    >> Share

    
    

    
    Radiat Oncol

51. REMMELINK MJ, El Awadly N, Arbeel-Weening B, Nadorp S, et al
    Correction: Impact of chemoradiotherapy for bladder cancer on pre-existing hydronephrosis and development of new hydronephrosis.
    Radiat Oncol. 2026;21:8.
    

    >> Share

    
    

    
    Sci Rep

52. YE Y, Chen Q, Huang Z, Huang Q, et al
    Preferred surgical strategies for bladder diverticular carcinoma.
    Sci Rep. 2025;16:917.
    

    >> Share

    
    
53. GUO C, Zhou Y, Liu X, Gao K, et al
    Analysis of the care needs of family caregivers of patients with bladder cancer undergoing urostomy: a cross-sectional study.
    Sci Rep. 2026 Jan 3. doi: 10.1038/s41598-025-34339.
    

    >> Share

    
    

    
    World J Surg Oncol

54. DAI P, Chen L, Dong Z, Wang H, et al
    LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a.
    World J Surg Oncol. 2026 Jan 7. doi: 10.1186/s12957-025-04171.
    

    >> Share

    
    

    
    World J Urol

55. PATTOU M, Robert G, Gouhizoun O, Guena F, et al
    Persistent lymph node uptake on [18 F]-FDG PET-CT after neoadjuvant chemotherapy: a major predictive factor of disease-free survival in MIBC.
    World J Urol. 2026;44:77.
    

    >> Share

    
    
56. ROESSLER N, Maiorano BA, Miszczyk M, Miyajima K, et al
    First-line treatments for BCG-naive non-muscle invasive bladder cancer: a systematic review and meta-analysis.
    World J Urol. 2026;44:76.
    

    >> Share

    
    

    
    Zhongguo Zhong Yao Za Zhi

57. SHAO YQ, Sheng DY, Guan YJ, Mi EX, et al
    [Mechanism of periplogenin in promoting Nrf2 degradation and inducing ferroptosis to inhibit bladder cancer].
    Zhongguo Zhong Yao Za Zhi. 2025;50:5790-5799.
    

    >> Share

    
    

    
    Zhonghua Bing Li Xue Za Zhi

58. 
    [Clinical pathological expert consensus on HER2 immunohistochemical testing in urothelial carcinoma(2026 version)].
    Zhonghua Bing Li Xue Za Zhi. 2026;55:7-15.
    

    >> Share

    
    

Free Medical Abstracts
Privacy Policy
Sponsors
Share